Insights on AI, medical research, and the future of scientific discovery.
Adaptive trials promise efficiency and flexibility - but they introduce complexity that can undermine the very rigour they are designed to preserve. Knowing when they add value is the question most sponsors skip.
Read more →
Data sovereignty is not a checkbox. It is an architectural decision. We built NousLab to work however your institution needs it to.
Read more →
Observational studies are the backbone of real-world evidence - and the source of most retractions. Getting the design right before data collection is the difference between credible findings and a desk reject.
Read more →
In most research teams, work is invisible until it is published. A shared research library makes ongoing work findable and reusable.
Read more →
Preprints accelerate scientific communication - but COVID-19 showed what happens when unreviewed findings become policy. The case for preprints is real, and so are the risks.
Read more →
Before you write a grant application, you need to find the right call. That search alone can take weeks. And then the writing starts.
Read more →
The studies that never reach PubMed - unpublished trials, internal reports, conference abstracts - can be decisive for the conclusions of a systematic review. Ignoring them is not a neutral choice.
Read more →
The worst time to discover relevant new evidence is when a reviewer points it out. Continuous monitoring with intelligent analysis prevents this.
Read more →
Meta-analysis is often treated as the gold standard of evidence - but pooling the wrong studies can produce a precise answer to the wrong question. Understanding when not to pool is as important as knowing how.
Read more →
Some research tasks are important but follow predictable patterns. Those are the tasks that AI agents can handle while you focus on the work that requires human judgment.
Read more →
Every major pharmaceutical company has announced an AI strategy. What they are actually doing, versus what they are announcing, is a more interesting question.
Read more →
If your evidence base already contains endpoint data from 50 comparable studies, starting a protocol from a blank template is wasted effort.
Read more →Join leading pharmaceutical companies, hospitals, biotech labs, CROs, and research centers using NousLab to accelerate medical breakthroughs.
Schedule a DemoTalk to our team to learn about licensing options for your organization